ASCO® 2024 Insights: "Multi-Center Phase II Trial Investigating Safety & Efficacy of Osimertinib + Consolidative SABR in Advanced EGFRm NSCLC"

Forgot your password?

Select specialty

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

Playback speed

June 10, 2024

Insights from 2024 WCLC

2024 ESMO Annual Meeting Insights Hub

K. Natsuhara

David Carbone

University of Colorado Cancer Center

AdventHealth

Mariam Alexander

David Carbone

2024 ASCO® Annual Meeting Insights Hub

Insights from 2024 WCLC

Insights from 2024 WCLC

I. Gil-Bazo, M. Brandão, B. Besse, E. Felip

2024 ASCO® Annual Meeting Insights Hub

Balazs Halmos

Total Health

Northwestern Medicine Oncology and Hematology

2024 ESMO Annual Meeting Insights Hub

Benjamin Herzberg

Springer Healthcare IME

Login

Login

Join VuMedi

ASCO® 2024 Insights: "Multi-Center Phase II Trial Investigating Safety & Efficacy of Osimertinib + Consolidative SABR in Advanced EGFRm NSCLC"

Study Overview & Key Takeaways

Trial Design & Patient Eligibility

Efficacy Results & Safety Profile

Study Limitations & Concluding Remarks

Management and Proactive Care of Adverse Events Associated with Loca…

Mechanisms of Resistance in Locally Advanced or Metastatic EGFR+ NSC…

Related Videos

WCLC 2024 Insights: Optimal Management of Malignant Pleural Effusion

ESMO 2024 Insights: Treatment Rechallenge After Grade 1 Trastuzumab-…

The Use of IO Doublet in PD-L1-Negative NSCLC

Metastatic EGFRm NSCLC: 1L Therapy Options

Clinical Highlights From AACR 2024: Trials Evaluating Selected New T…

Lazertinib in 1L EGFR-Mutant NSCLC: Unique Mechanism and Benefits of…

Multidisciplinary Panel Discussion: New Treatment Options for Surgic…

Surveillance Imaging in Solid Tumors: More Complicated Than It Appea…

ASCO® 2024 Lung Cancer Highlights: Top Abstracts Including BEAT-SC, …

WCLC 2024 Insights: MARIPOSA - Amivantamab + Lazertinib vs. Osimerti…

WCLC 2024 Insights: Interstitial Lung Disease and Lung Cancer - How …

ESMO 2024 Summary: EGFRm NSCLC Panel Discussion - MARIPOSA, PAPILLON…

ASCO® 2024 Lung Cancer Highlights: CROWN, LAURA, ADRIATIC, and PALOM…

Year in Review: Lung Cancer

Treatment Updates in Advanced and Metastatic NSCLC - Advances in Tho…

Hyperprogression in Cancer Treated With Immunotherapy

ESMO 2024 Summary: Developmental Therapeutics Highlights

Pan-KRAS Inhibition: Insights Into NSCLC and Beyond

Biopsies in Lung Cancer: Tumor vs. Liquid

New Frontiers in Oncology: Advanced Diagnostics and Therapeutics